BIAF

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders at the Company’s annual meeting held on April 30, 2026. As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 09076W406. As a result of the reverse stock split, every 15

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity's commercial reach through AvMEDICAL's existing sales team  Service-Disabled Veteran-Owned AvMEDICAL provides access to established government procurement channels bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced it has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB) and established distributor of premium medi

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock. The combined effective offering price for each pre-funded warrant and accompanying two warrants to be issued is $0.4657.The pre-funded warrants will have an exercise

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock. The combined effective offering price for each pre-funded warrant and accompanying two warrants to be issued is $0.4657. The pre-funded warrants will have an exercise price of $0.007 per share of common stock, and the warrants will have an initial exercise price of $0.4727 per share, will be exercisable following stockholder ap

JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules. The combined effective offering price f

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant) and accompanying two warrants to be issued is $0.4727. The combined effective offering price for each pre-funded

10-Q - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical trial Pipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeutics bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases and topically delivered therapeutics for squamous and basal cell skin cancers, today reported financial results and business highlights for the quarter ended June 30, 2026. Q2 2026 Highlights and Recent E

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating CyPath® Lung into pulmonary nodule evaluation and cance

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a c

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for CyPath® Lung, its noninvasive lung cancer diagnostic, with more than 200% growth year-over-year. The number of tests sold in the second quarter of 2026 represen

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs (siRNAs) that kill squamous and basal skin cancer cells in vitro while leaving non-cancerous skin cells unharmed. The newly released findings support the Company’s efforts to develop topical treatments for squamous cell and basal cell carcinoma, two of the most

8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the closing of its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.The offering consisted of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for

424B4 - bioAffinity Technologies, Inc. (0001712762) (Filer)